Michael A.S. Johnson*†, Hannah Smith†, Priya Joseph†, Robert H. Gilman*†, Christian T. Bautista*‡, Kalina J. Campos*§, Michelle Cespedes†, Peter Klatsky†, Carlos Vidal¶, Hilja Terry†, Maritza M. Calderon*§, Carlos Coral†, Lilia Cabrera†, Paminder S. Parmar†, and Joseph M. Vinetz#
Author affiliations: *Asociación Benéfica Prisma, Lima, Peru; †Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; ‡U.S. Naval Medical Center Research Detachment, Lima, Peru; §Universidad Peruana Cayetano Heredia, Lima, Peru; ¶Ministry of Health, Iquitos, Peru; #University of California San Diego School of Medicine, La Jolla, California, USA
Figure 3. Prevalence of antileptospiral immunoglobulin (Ig) M/IgG antibodies by age group. Number above each bar is the sample size for the specified age group and site. The trend of increasing prevalence by age is significant for Belen and the rural communities (p = 0.018 and p = 0.012, respectively).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.